Rise and shine, everyone, another busy day is on the way. This is a fast-paced world, after all, and trying to keep up takes diligence and, yes, a few cups of stimulation. So please join us as we indulge in another round of cinnamon dolce. As always, feel free to join us. Remember, your neurons need nurturing. Meanwhile, here are a few tidbits to help you along. We hope your day is productive and successful. And of course, please do keep in touch. We appreciate the postcards and letters.

A top Food and Drug Administration official says new drugs to treat patients already infected with the novel coronavirus, which has sparked outbreaks across multiple continents, will emerge much more quickly than vaccines to prevent infection, STAT reports. “The development of a vaccine is not going to prevent a pandemic here,” says Peter Marks, the director of the FDA Center for Biologics Evaluation and Research. And he adds, getting a vaccine ready for pivotal testing is going to take more than just a few months.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy